Rainbow Childrens Medicare Ltd
Rainbow Childrens Medicare Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Get Rainbow Childrens Medicare Ltd's next results in your feed
Guidance rank: #11 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Revenue growth guidance remains in the late teens to around 20%, supported by bed additions and recent acquisitions. Rainbow Children’s Medicare expects late teens to around 20% revenue growth in the near term, supported by bed additions and acquisitions.
From Rainbow Childrens Medicare Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Revenue growth guidance remains in the late teens to around 20%, supported by bed additions and recent acquisitions.
- Addition of roughly 350 beds expected this year (250 coming into operation in 2-3 months plus 100 from recent Warangal acquisition).
- New hospitals like Sarjapur have reached breakeven; Anna Nagar nearing breakeven within six months.
- Expansion into new geographies such as NCR, Pune, and Northeast underway, targeting cities with strong IT and knowledge-based job ecosystems.
- Continued focus on strengthening sales and marketing teams to achieve sustainable, scalable growth.
- The project pipeline is intact, with timelines for new hospitals (e.g., Gurugram operations targeted around September-October 2027).
2 more points from Rainbow Childrens Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rainbow Childrens Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company invested approximately INR 41.5 crores in capital expenditure during the quarter.
- They are advancing an asset-light build-to-suit greenfield hospital in Pune with 150 beds, expected to cost around INR 80 lakhs per bed, with signing anticipated within weeks.
- The Pune hospital is planned to commence operations approximately 2.5 years after signing.
- The Rajahmundry 100-bed regional hub hospital project is complete and awaiting government permissions to begin operations.
- Two spoke hospitals in Bengaluru are targeted for commissioning this year.
2 more points from Rainbow Childrens Medicare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rainbow Childrens Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Rainbow Childrens Medicare Ltd's call on order book
Create a free account to keep reading this call
Rainbow Childrens Medicare Ltd — Quarterly revenue & net profit
Rainbow Childrens Medicare Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 353 | 330 | +7% | 370 | -4.6% |
| Operating profit (EBITDA) | 104 | 94 | +10.6% | 115 | -9.6% |
| Operating margin | 29% | 28% | +1 pp | 31% | -2 pp |
| Profit before tax | 71 | 53 | +34% | 77 | -7.8% |
| Net profit (PAT) | 54 | 40 | +35% | 57 | -5.3% |
| EPS (₹) | 5.27 | 3.89 | +35.5% | 5.55 | -5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹548 Cr, net profit ₹84 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rainbow Childrens Medicare's management said in earlier quarters
Others in Healthcare Services this season
- Aster DM Quality Care Ltd (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Syngene International (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospital & Trauma Care Services (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rainbow Childrens Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rainbow Childrens Medicare Ltd Q1 FY26 results?
Revenue growth guidance remains in the late teens to around 20%, supported by bed additions and recent acquisitions. Rainbow Children’s Medicare expects late teens to around 20% revenue growth in the near term, supported by bed additions and acquisitions.
What is Rainbow Childrens Medicare Ltd share price analysis?
Rainbow Childrens Medicare Ltd currently shows a neutral. The stock trades at a P/E of 56.7 with a market cap of ₹16,236 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rainbow Childrens Medicare Ltd planning capital expenditure?
The company invested approximately INR 41.5 crores in capital expenditure during the quarter.
Keep Rainbow Childrens Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.